泰格醫藥(03347.HK):杭州泰鯤股權投資基金合夥企業已成立
格隆匯8月23日丨泰格醫藥(03347.HK)公佈,就公司下屬投資平台泰格股權與杭州市國有資本投資運營有限公司的全資子公司杭州產業投資有限公司、杭州高新創業投資有限公司以及泰瓏投資共同發起設立生物醫藥產業基金事宜,公司獲吿知基金已於2021年8月10日成立,並根據中國適用法律及法規向中國證券投資基金業協會完成基金成立的備案手續。
據悉,該基金名稱名為杭州泰鯤股權投資基金合夥企業(有限合夥),經營範圍一般項目:股權投資;創業投資(限投資未上市企業);執行事務合夥人為杭州泰瓏創業投資合夥企業(有限合夥)(委派代表:劉春光)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.